{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138272","form_type":"8-K","ticker":null,"cik":"0001796129","company_name":"Vincerx Pharma, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.154108+00:00","generated_at":"2026-06-02T01:05:55.873923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vincerx Pharma Q1 2024 net loss $12.4M ($0.58/sh); cash $5.1M plus $17.8M financing through 2024","bullets":["Cash $5.1M at Mar 31, 2024; April financing of ~$17.8M extends runway through 2024.","Net loss $12.4M ($0.58/sh) vs $14.6M ($0.69/sh) in Q1 2023; R&D spend $4.6M down from $10.9M.","VIP943 Phase 1 in fourth cohort; no dose-limiting toxicities in 11 pts; preliminary PK shows minimal circulating payload.","Enitociclib NIH combo study: four PRs in PTCL and one PR in tFL monotherapy; 63 pts enrolled overall.","VIP236 Phase 1 signs of tumor reduction and improved safety profile; updated data expected by end of Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138272","json":"https://secwatch.observer/filing/0001193125-24-138272.json","markdown":"https://secwatch.observer/filing/0001193125-24-138272.md","text":"https://secwatch.observer/filing/0001193125-24-138272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/0001193125-24-138272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/d825581d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:05:55.873923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8454587cdd9ef10f010e4e71158139d409ab21fc","claim":"Vincerx Pharma, Inc. reported financial results for first quarter of 2024.","evidence_excerpt":"On May 14, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796129/000119312524138272/0001193125-24-138272-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}